Showing posts with label neurodegenerative disorder. Show all posts
Showing posts with label neurodegenerative disorder. Show all posts

Wednesday, October 07, 2026

Uncovering 76 environmental exposures linked with Alzheimer’s and related dementias. Really!

Why not 100 exposures? Is such a large number of exposures even useful?

"... The study identified 76 exposures significantly linked with ADRD and 34 linked with Alzheimer’s disease specifically. ..."

From the abstract:
"INTRODUCTION
Environmental exposures contribute substantially to Alzheimer's disease and related dementias (ADRD), yet comprehensive exposome-wide investigations systematically evaluating multi-domain environmental factors remain limited and lacking utility for precision medicine.

METHODS
We conducted an exposome-wide association study (ExWAS) among 499,992 UK Biobank participants, examining 193 exposures across five domains (social, physical, chemical, lifestyle, and ecosystems).
Cox proportional hazard models with Bonferroni correction identified ADRD-associated exposures. We used the XGBoost classifier to build a predictive model and further developed an exposomic risk score (ERS) for risk stratification.

RESULTS
During a 15.3-year median follow-up, 8881 participants (1.77%) developed ADRD, including 4000 with Alzheimer's disease.
ExWAS identified 76 exposures after Bonferroni correction. The prediction model achieved area under the curve (AUC) = 0.718, outperforming demographics+apolipoprotein E (APOE) status alone (AUC = 0.678). The ERS stratified ADRD risk (highest vs lowest quartile hazard ratio [HR] = 2.97, 95% confidence interval [CI]: 2.59–3.41).

DISCUSSION
The ERS has the potential to contribute to clinically relevant prevention strategies for ADRD."

Uncovering environmental exposures linked with Alzheimer’s and related dementias | Harvard T.H. Chan School of Public Health



Fig. 1 Analytic workflow of the study.


Wednesday, September 23, 2026

Neuron Stimulation Improves Symptoms in Mouse Model of Huntington’s Disease

Good news!

"... An international team of neuroscientists wondered if they could rebalance these damaged neural circuits. In a mouse model of Huntington’s disease, the researchers stimulated specific brain cells near the damaged ones within the circuits. This stimulation caused the motor cortex to function more normally, enabling the mice to learn new motor skills and improving their behavioral symptoms for days. The researchers report their findings in the July issue of Nature. ..."

From the abstract:
"Huntington’s disease (HD) is a devastating movement disorder without a cure at present. Although the monogenic basis of HD is well defined, the complex downstream effects that underlie behavioural symptoms are poorly understood. These effects include cortical dysfunction, yet the roles of specific cortical neuronal subtypes in HD symptoms remain largely unexplored.
Here we used longitudinal in vivo two-photon calcium imaging to examine the activity of three cortical inhibitory neuron (IN) subtypes and excitatory corticostriatal (CStr) projection neurons in the motor cortex of the transgenic R6/2 HD mouse model throughout disease progression. We found that motor deficits in R6/2 mice were accompanied by neuron subtype-specific abnormalities in movement-related activity. This included marked hypoactivity of vasoactive intestinal peptide (VIP)-INs and CStr neurons, which was also observed in the knock-in zQ175DN HD mouse model.
Optogenetic activation of VIP-INs in R6/2 mice restored healthy levels of activity in VIP-INs and their downstream CStr neurons and ameliorated motor deficits in R6/2 mice; behavioural improvements persisted for days after stimulation. Our findings highlight cortical INs as a potential therapeutic target for HD."

Neuron Stimulation Improves Symptoms in Mouse Model of Huntington’s Disease "Using targeted light stimulation, scientists successfully recalibrated damaged brain circuits to restore movement and motor learning in mice."



Fig. 3: Optogenetic activation of VIP-INs normalizes VIP-IN and CStr neuron activity.


Wednesday, September 09, 2026

New clues suggest how destructive immune cells wreak havoc in the brain from the neck

Good news! The best part is that a treatment of the lymph nodes in the neck can be very effective.

"In recent years, scientists have found CD8+ T cells—immune cells that recognize and respond to foreign threats—in the brain tissue of people who died with Alzheimer’s, and evidence suggests that they were harming, not helping. Now, researchers report that a type of dendritic cell in lymph nodes in the neck helps prime these T cells to multiply before they enter the brain and cause damage.

In mice bred to produce excess toxic tau, a key Alzheimer’s protein, those with the dendritic cells developed the expected severe brain damage.
Animals without the dendritic cells did not experience the same T cell infiltration, severe neurodegeneration or behavioral problems—even though they still had excess tau.

This finding suggests that while tau may not be completely harmless by itself, inflammation driven by T cells may amplify the damage. The T cells proliferated in the mice’s neck lymph nodes, where they were primed by the dendritic cells. The fact that this process occurs in the neck, not the brain, opens the door to using existing drugs that trap T cells in lymph nodes. ..."

"... Researchers ... have now discovered in mice that these immune cells, known as T cells, are receiving their instructions from lymph nodes outside of the brain. The team also showed they can block these instructions to dramatically mitigate neurodegeneration. The discovery reveals a previously unsuspected pathway that could potentially halt or slow the progression of Alzheimer’s disease and other diseases collectively called primary tauopathies ..."

From the abstract:
"Alzheimer’s disease and primary tauopathies are marked by changes in adaptive immunity, with increased brain CD8+ T cells correlating with tau pathology severity.
However, how peripheral T cells get primed to enter the brain and contribute to tau-mediated neurodegeneration remains unclear.
In different disease conditions, conventional type 1 dendritic cells (cDC1s) cross-present antigens to prime CD8+ T cells into effector cells.
We show that tauopathy mice lacking cDC1s or antigen cross-presentation are protected from neurodegeneration, with reduced brain CD8+ T cell infiltration and glial activation.
The remaining CD8+ T cells exhibit limited clonal expansion, consistent with impaired priming.
We further demonstrate that brain-derived antigens are presented in secondary lymphoid tissues, suggesting a site of T cell activation.
Together, these findings establish cDC1-dependent peripheral priming as a key driver of CD8+ T cell accumulation in the brain and tau-mediated neurodegeneration."

ScienceAdviser

New clues suggest how destructive immune cells wreak havoc in the brain (no public access) "Study in mice strengthens T cells’ ties to neurodegenerative conditions like Alzheimer’s"

Key path to Alzheimer’s-like brain damage starts outside the brain (original news release) "Study finds in mice that immune cells that drive neurodegeneration originate in body’s lymph nodes"



Fig. 4: cDC1 deficiency specifically prevents CD8+ T cells from accumulating in brain of tauopathy mice at 9.5 months of age.


Thursday, August 20, 2026

Tuberculosis Vaccine (BCG) Reprograms Brain Immunity in Small Trial

Amazing stuff! Good news, but older news!

"... Since then, with billions of doses given, the shot has surprised scientists with its capabilities beyond preventing tuberculosis. Researchers have found that BCG also helps prevent type 1 diabetes, reduce multiple sclerosis relapse, and treat bladder cancer. Scientists have uncovered how BCG programs the peripheral immune system to induce these effects.

However, the vaccine’s impact on the central nervous system (CNS) and immune cells within it remains poorly understood, despite retrospective studies revealing a link between the vaccine and the brain: People who received BCG for bladder cancer also showed reduced incidence of Alzheimer’s disease (AD).

Now, in a small clinical trial, researchers found that BCG triggered immune remodeling in the cerebrospinal fluid (CSF) of older adults and reduced AD-related biomarkers. The findings, published in Communications Medicine, suggest that vaccine-induced immune reprogramming could be used as a strategy to target early neurodegeneration. ..."

From the abstract:
"Background
Immune aging may contribute to Alzheimer’s disease. Bacillus Calmette–Guérin (BCG), a vaccine known to induce trained immunity, has been linked to reduced Alzheimer’s risk in prior studies. However, whether trained immunity can be observed in the human central nervous system remains unclear. We assessed whether BCG induces trained immunity–like responses in adults with and without Alzheimer’s-related changes.

Methods
We conducted two related one-year, open-label clinical trials in adults aged 55 years or older (n = 12 without Alzheimer’s-related pathology; n = 11 with Alzheimer’s-related pathology) recruited at a single center.
Participants received two intradermal BCG vaccinations one month apart. Protocol-defined objectives included safety, neurocognitive outcomes, and longitudinal immune and Alzheimer’s biomarker changes in blood and cerebrospinal fluid.
Immune responses were assessed using cytokine assays and single-cell profiling. All enrolled participants were included where data were available; longitudinal changes were analyzed using mixed-effects models.

Results
Here we show that BCG induces persistent, trained immunity–like changes in immune cells in cerebrospinal fluid, including enhanced innate responsiveness and associated transcriptional programs.
These responses differ from blood, suggesting compartment-specific immune imprinting.
In participants without Alzheimer’s-related changes, these immune shifts are accompanied by decreased amyloid-β levels in cerebrospinal fluid and increased levels in blood. BCG was well tolerated, with no unexpected safety signals observed.

Conclusions
These findings suggest trained immunity–like responses in the central nervous system that may influence Alzheimer’s-relevant pathways.
This approach may represent an early neurodegenerative intervention strategy, although larger controlled studies are needed to confirm these observations."

BCG Vaccine Reprograms Brain Immunity in Small Trial | The Scientist "The BCG vaccine altered Alzheimer’s disease biomarkers and brain immune cells in older adults, hinting at its potential to target neurodegeneration."



Fig. 1: Study design and trained immunity-associated cytokine responses in PBMCs. [Peripheral blood mononuclear cells]


Fig. 2: BCG induces compartment-specific transcriptional training in human monocytes.


Tuesday, August 18, 2026

Estrogen-only menopausal hormone therapy linked to fewer Alzheimer’s hallmarks in women

Good news!

Notice how Stanford University strenuously avoids to mention women in the first article below even though this health subject is about women!!! A typical case of deplorable ideology and indoctrination? It is certainly very strange!

"In brief
  • Stanford Medicine researchers examined autopsied brains for Alzheimer’s defining pathological hallmarks to learn how menopausal hormone therapy relates to the disease.
  • The study found that estrogen-only therapy was associated with fewer of these Alzheimer’s hallmarks and better performance on memory tests and in the ability to function independently.
  • The finding challenges a longstanding recommendation against hormone therapy for memory decline and points to a possible benefit against dementia for women who reach menopausal age without a uterus.
...

The study ... is the first to measure the connection between menopausal hormone therapy, or MHT, and reductions in Alzheimer’s-related pathological deposits in autopsied brains. ..."

From the abstract:
"Background and Objectives
Although evidence suggests that the neurophysiologic impact of estrogen decline during menopause may contribute to increased risk of Alzheimer disease (AD) in women, the effect of menopausal hormonal therapy (MHT) on AD risk requires further study. We sought to examine the associations between MHT use and neuropathologic, clinical, and imaging/fluid biomarker outcomes.

Methods
In this cohort study, we tested the association between estrogen-only MHT use and dementia outcomes in female participants using 2 independent, large-scale data sets:
National Alzheimer's Coordinating Center (NACC) and
Alzheimer's Disease Neuroimaging Initiative (ADNI).
Participants included women 50 years and older with self-reported use of estrogen-only MHT or no self-reported use of MHT. Clinical, imaging/fluid biomarker, and neuropathologic outcomes were examined. Research was performed at academic medical centers.

Results
Neuropathologic data were collected from
NACC for 258 MHT users (mean age of death = 81.9, SD = 19.5) and 2,701 non-MHT users (mean age of death = 82.2, SD = 11.0).
The ADNI cohort included 110 MHT users (mean age = 76.5, SD = 7.5) and 1,948 non-MHT users (mean age = 73.2, SD = 8.9).
The odds of increased AD pathology on autopsy (primary outcome) were significantly decreased in MHT users relative to nonusers (odds ratio [OR] 0.65, 95% CI 0.48–0.88, p = 0.005).
MHT use was associated with secondary outcomes including significantly decreased amyloid pathologic load assessed through plasma (β = 0.44, 95% CI 0.16–0.73, p = 0.0025) and CSF (β = 0.07, 95% CI 0.002–0.13, p = 0.030).
MHT use was associated with significantly lower odds of clinical dementia diagnoses (OR 0.61, 95% CI 0.55–0.67, p < 0.0001) and lower odds of symptoms of memory/functional decline (OR 0.67, 95% CI 0.61–0.74, p < 0.0001).

Discussion
Our findings demonstrate small but significant associations between MHT use during later life and a range of AD-related neuropathologic and clinical outcomes in 2 large cohorts of female participants.
Although our results do not address causality and have limited generalizability due to the retrospective nature of the study, they suggest a protective effect of MHT use in the dementia course."

Estrogen-only therapy linked to fewer Alzheimer’s hallmarks | Stanford Report "Some studies have reported that estrogen-only menopausal hormone therapy raises dementia risk. New research on Alzheimer’s disease hallmarks in autopsied brains indicates the opposite."

Study ties estrogen-based menopausal hormone therapy to lower Alzheimer’s risk "Some studies have reported that menopausal hormone therapy raises dementia risk. A new study that analyzed Alzheimer’s-disease hallmarks in autopsied brains indicates the opposite."

Wednesday, July 22, 2026

Headbutting gives goats brain damage. Really!

Why should it be different from human beings? Will these animals become a model to study human neurodegenerative disorders?

From the abstract:
"Traumatic brain injury (TBI) is a characteristic feature of neurodegenerative diseases such as Alzheimer’s disease and chronic traumatic encephalopathy. Small animal models have been used to establish clinically relevant biomarkers of neuropathology, however, they show significant anatomical differences from humans and are affected by artificial experimental manipulations, making them often unsuitable for longitudinal study of repetitive mild TBI. There is a need for more diverse and translationally relevant animal models to better understand disease onset and development.

Building on a previous study of neuropathology in headbutting bovids in the wild, this pilot study investigated whether freely headbutting domestic goats, which naturally engage in low-intensity, high-frequency head impacts, accumulate measurable biomarkers of neurodegeneration in cerebrospinal fluid (CSF) and brain tissue. Over a six-month period, three male goats (Capra hircus) were allowed to freely headbutt under continuous video surveillance.
Monthly CSF samples were collected, and concentrations of key neurodegeneration biomarkers were measured via multiplex immunoassays, including amyloid-β peptides (Aβ40, Aβ42), total and phosphorylated tau (tTau and pTau), glial fibrillary acidic protein (GFAP), S100 calcium-binding protein B (S100B), and neurofilament M (NF-M). Imaging studies were completed for non-invasive assessment of glucose metabolism ([18F]-FDG) and neuroinflammation via translocator protein (TSPO, [18F]DPA-714).
Postmortem immunohistochemistry was conducted on prefrontal cortical tissues using antibodies targeting pTau, GFAP, and S100B. Head impact kinematics were quantified using horn-mounted accelerometer and inclinometer sensors that recorded linear acceleration, rotational velocity, and head orientation during naturally occurring headbutting events.

Several notable trends were observed. Phosphorylated tau as well as reactive astrocytes were detected in the brain tissue, mirrored by elevated GFAP detected in the CSF. PET TSPO did not illustrate a significant signal, however, PET FDG revealed frontal-dominant activity in all goats, and one with asymmetrical activation.
Overall, the goats sustained 5,000-7,000 head impacts each over six months. Accelerometer measurements recorded forces up to 388 N and peak acceleration up to 16.5 g.
This multi-modal observational study is the first to characterize neurodegeneration biomarkers and kinematics in headbutting goats.
Even at one year old, the combination of pTau and gliosis in both the brain tissue and CSF indicates that the goat’s repetitive head impacts begin to show neurodegenerative consequences early in life.
Likely, the severity of these consequences increases with headbutts and age, eventually resulting in chronic neurodegeneration. This system shows promise as a large-animal model for the longitudinal study of the onset and progression of neurodegenerative disease."

ScienceAdviser

Friday, May 01, 2026

Damage to brain’s white matter may play key role in neurodegenerative disease, and could be target for future treatments

Good news!

"... The team ... created localised damage to myelin – the main component of white matter – in a well-defined brain circuit and followed what happened over time. They found that small, localised myelin damage triggered a striking response in a connected, remote grey matter region. Neuronal activity fell, microglia – the brain’s immune cells – became activated, and connections between neurons were lost.

Crucially, these changes were not permanent. After myelin was regenerated, neuronal activity recovered, connections between neurons returned, and the inflammatory response subsided.

The study also challenges a common assumption about brain inflammation. Grey matter inflammation is traditionally viewed as harmful. But here, the team found that this transient response was part of the repair process itself. When they prevented grey matter inflammation, myelin regeneration was impaired.

Conversely, when the team blocked myelin regeneration, the grey matter response did not resolve and instead became chronic. This suggests that failed myelin regeneration may help drive the persistent low-grade inflammation seen in neurodegenerative disease. ..."

"Focal white matter lesions occur in most neurodegenerative disorders. Despite occurring early in disease, white matter lesions are considered to be independent of, or secondary to, grey matter neuroinflammation, synapse loss and altered neuronal activity. Notably, their functional effect on neuronal circuits remains understudied.
To address this, we generated a focal white matter lesion in the rat brain within a clinically relevant, anatomically well-defined circuit, in which these lesions occur in many neurodegenerative disorders.
Here we show that focal white matter lesions evoke transient neuronal activity changes and microgliosis, with subsequent synapse loss and increased microglial engulfment in the grey matter, which is reversed if myelin regeneration completes. Grey matter microgliosis is often considered to be detrimental; however, we show that it is an integral part of regeneration and is conserved across three distinct mouse circuits and lesioning methods.
Preventing these transient changes in the grey matter blocks myelin regeneration in the white matter.
Conversely, inducing myelin regeneration failure leads to chronic grey matter neuroinflammation. This recapitulates the low-grade inflammation considered to be a dominant mechanism underlying neurodegeneration.
Our findings reveal a form of regenerative plasticity coupling white matter integrity to grey matter function, which may underlie multiple neurodegenerative conditions, and highlight the potential of targeting myelin regeneration to prevent chronic neuroinflammation."

Damage to brain’s white matter may play key role in neurodegenerative disease, and could be target for future treatments | University of Cambridge "Damage to white matter in the brain can trigger features associated with neurodegenerative disease ..."



Fig. 3: Focal white matter lesions evoke changes in microglial states and neuronal mitochondria.


Sunday, April 12, 2026

Cannabidiol (CBD) further confirmed to reverse brain damage in mouse model of Alzheimer's disease

Good news!

"... The non-psychoactive compound derived from the Cannabis sativa plant, called cannabidiol (CBD), was recently found to show promise for protecting brain cells from damage.

Compared to Δ9-tetrahydrocannabinol (THC), the compound in cannabis that elicits feelings of euphoria and alters a user's mental state, CBD is safer and could thus be easier to introduce in clinical settings. ...

Du and her colleagues studied a mouse model of AD known as triple-transgenic AD mice. These are genetically modified mice whose synapses become progressively damaged, following the formation of Tau protein tangles and the accumulation of Aβ. These mice exhibit characteristics that resemble those observed in patients with AD, such as memory loss and anxiety-like behaviors.

First, the researchers treated the mice with CBD six days per week for a total period of 45 days. After this treatment period, they observed the mice's behavior and examined their brains.

Interestingly, they found that the mice's memory had improved after treatment and their anxiety levels appeared lower. In addition, dendritic spines in their brains and the overall structure of synapses (i.e., junctions between neurons) appeared to be restored.

"We next looked at how CBD achieves the effects we observed," said Du. "We found that it activates the TrkB-PI3K-AKT pathway—a critical pathway for neuronal survival and plasticity. ..."

From the abstract:
"Alzheimer’s disease (AD) is characterized by progressive synaptic failure, neuroinflammation, amyloid and tau pathology, yet effective disease-modifying therapies remain limited. Cannabidiol (CBD) has shown neuroprotective potential in AD, but its direct molecular targets and signaling mechanisms remain unclear. Here, we demonstrate that CBD ameliorates cognitive and emotional deficits in 3×Tg-AD mice by restoring synaptic integrity and plasticity.
At the mechanistic level, CBD activated TrkB signaling independently of BDNF, leading to suppression of tau hyperphosphorylation via the PI3K/AKT/GSK3β pathway and attenuation of neuroinflammation and amyloid pathology through inhibition of the JAK2/STAT3/SOCS1 axis.
Using isothermal shift assays combined with biophysical binding analyses, we identified FRS2, a core adaptor protein of TrkB, as a direct molecular target of CBD. 
Molecular dynamics simulations further revealed that CBD stabilizes the FRS2–TrkB interface, thereby facilitating TrkB activation.
Importantly, genetic knockdown of FRS2 abolished CBD-induced TrkB signaling and its downstream neuroprotective effects in both cellular and in vivo AD models. Together, these findings identify FRS2 as a critical signaling node mediating BDNF-independent TrkB activation by CBD and establish a mechanistic framework linking CBD to disease-modifying pathways in AD."

CBD found to reverse brain damage in mouse model of Alzheimer's disease

Monday, March 16, 2026

Parthanatos pathway behind neuron loss in multiple sclerosis identified

Good news! This research indicates possible new treatment options!

"... Researchers... recently carried out a mouse study investigating the possible contribution of a specific molecular process that leads to cell death, called parthanatos, in the loss of neurons resulting from neuroinflammation, such as that associated with MS. Their findings ... suggest that damage to neurons associated with MS is caused by immune responses that trigger internal cell death programs. ...

The researchers subsequently blocked the final stage of parthanatos using genetic pharmacological approaches to inhibit MIF nuclease activity. MIF nuclease is the enzyme responsible for DNA damage in parthanathos. Remarkably, they found that blocking this enzyme reduced DNA fragmentation, led to the survival of more neurons and significantly lowered the severity of the symptoms presented by mice. ..."

From the abstract:
"Central nervous system inflammation is implicated in neurodegeneration across several disorders, including multiple sclerosis (MS). While marked therapeutic progress has been made in preventing relapses in MS, primary neuroprotection in this disease remains elusive. This, in part, is due to an incomplete understanding of the molecular pathways involved in immune-mediated neuronal death.
Here we show that parthanatos, a recently described caspase-independent and DNA damage-induced cell death program, contributes to neuron death in the experimental autoimmune encephalomyelitis (EAE) mouse model of autoimmune neuroinflammation.
We reveal that DNA damage increases in neurons during EAE, and that neurons are progressively lost over the disease course. Neurons in affected areas display intracellular hallmarks of the parthanatos cascade.
Genetic or pharmacologic blockade of the final step in parthanatos, genomic fragmentation by macrophage migration inhibitory factor (MIF) nuclease, reduces neuron loss and disease severity.
Transcriptomic characterization of neurons with and without MIF nuclease activity reveals parthanatos-dependent differences in response to EAE. Together, this work establishes parthanatos as a key mechanism of neuron cell death during neuroinflammation."

Parthanatos pathway behind neuron loss in multiple sclerosis identified



Fig. 2: Accumulation of parthanatos markers in lumbar spinal cord neurons during EAE.


Saturday, February 07, 2026

Scientists uncover why some brain cells resist Alzheimer's disease and they identified a key player

Good news!

"Key takeaways
  • Tau is the most common protein that aggregates in neurodegeneration diseases. However, researchers had not determined why some types of neurons are affected more than others.
  • The work identified a protein complex called CRL5SOCS4 that marks tau for degradation. The findings suggest that strengthening this natural defense mechanism could represent a new therapeutic strategy for neurodegenerative diseases.
  • Enhancing CRL5SOCS4 activity could help neurons clear tau more effectively, while strategies to maintain proteasome function during stress might prevent the formation of toxic tau fragments.
...

uncovered why certain brain cells are more resilient than others to the buildup of a toxic protein that is a hallmark of Alzheimer’s disease and related dementias ...

used a novel CRISPR-based genetic screening approach on lab-grown human brain cells to determine the cellular machinery that controls the accumulation of tau protein in the brain. ...

Among more than 1,000 genes identified, the CRL5SOCS4 protein complex emerged as a key player that attaches molecular tags to tau, marking it for destruction by the cell’s recycling machinery.

Importantly, analysis of brain tissue from Alzheimer’s patients revealed that higher expression of CRL5SOCS4 components made neurons more likely to survive despite the accumulation of tau protein. 

The study also revealed an unexpected connection between mitochondrial dysfunction and tau toxicity. When the researchers disrupted the cellular powerhouses that generate energy, they triggered the production of a specific tau fragment approximately 25 kilodaltons in size. This fragment closely resembles a biomarker found in the blood and spinal fluid of Alzheimer’s patients, known as NTA-tau. ..."

From the highlights and abstract:
"Highlights
• CRISPR screens in human neurons reveal modifiers of tau oligomer accumulation
• CUL5 and the substrate-specific adaptor SOCS4 function as tau E3 ubiquitin ligase
• Expression of CUL5 complexes is correlated with resilience in tauopathies
• Reactive oxygen species generate a disease-relevant tau proteolytic fragment

Summary
Aggregation of the protein tau defines tauopathies, the most common age-related neurodegenerative diseases, which include Alzheimer’s disease and frontotemporal dementia. Specific neuronal subtypes are selectively vulnerable to tau aggregation, dysfunction, and death. However, molecular mechanisms underlying cell-type-selective vulnerability are unknown. To systematically uncover the cellular factors controlling the accumulation of tau aggregates in human neurons, we conducted a genome-wide CRISPRi screen in induced pluripotent stem cell (iPSC)-derived neurons. The screen uncovered both known and unexpected pathways, including UFMylation and GPI anchor biosynthesis, which control tau oligomer levels. We discovered that the E3 ubiquitin ligase CRL5SOCS4 controls tau levels in human neurons, ubiquitinates tau, and is correlated with resilience to tauopathies in human disease. Disruption of mitochondrial function promotes proteasomal misprocessing of tau, generating disease-relevant tau proteolytic fragments and changing tau aggregation in vitro. These results systematically reveal principles of tau proteostasis in human neurons and suggest potential therapeutic targets for tauopathies."

Scientists uncover why some brain cells resist Alzheimer's disease | UCLA "Study identifies cellular defense system that protects neurons from toxic tau proteins, opening door to new treatments"



Graphical abstract


Saturday, January 31, 2026

A new molecular atlas of tau enables precision diagnostics and drug targeting across neurodegenerative diseases

Good news!

"Tau protein aggregation is a shared feature in over 20 neurodegenerative diseases (collectively referred to as "tauopathies"). New research led by Boston Children's Hospital challenges the current "one-size-fits-all" approach to diagnosing and treating these tauopathies. ...

analyzed brain tissue from 203 patients spanning several tauopathies, including Alzheimer's disease and chronic traumatic encephalopathy (CTE). They used a novel mass spectrometry tool called FLEXITau which enables absolute quantification of pathological tau species, measuring both the identities and abundances of disease-relevant chemical modifications. ...

that tau chemistry changes as the disease advances, and that the p217 Tau modification ranked as the most accurate diagnostic for Alzheimer's. p217 is now an FDA-approved diagnostic marker for Alzheimer's disease. ...

Using FLEXITau, the researchers identified 145 post-translational modifications and 195 cleavage sites across tau. Machine-learning models then ranked the molecular features that best distinguished each disease based on quantified chemical changes. ..."

From the highlights and abstract:
"Highlights
• Comprehensive mapping of tau identifies 145 PTMs and 195 cleavage sites in tauopathies
• Provides tau molar abundance and peptide modification stoichiometry in disease
• Machine learning classifies tauopathies using tau molecular features
• Identified disease-specific features are potential drug targets and diagnostics

Summary
In Alzheimer’s disease (AD), pathological tau protein shows a progressive accumulation of post-translational modifications (PTMs), reflecting disease severity, progression, and prion-like activity. Although many neurodegenerative diseases with dementia display tau aggregates, the pathological proteoforms of tau protein from each disease type remain unknown.
Here, using a quantitative mass spectrometry-based proteomics platform, FLEXITau, deep characterization of pathological tau protein isolated from the brains of 203 human subjects with AD, familial AD (fAD), chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), Pick’s disease (PiD), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB)—a non-tauopathy symptomatic control—and healthy controls (CTR) is performed. Unsupervised data analyses and supervised machine learning identify distinct molecular features of pathological tau for each disease, enabling molecular disease stratification.
This study identifies potential disease-specific biomarkers and therapeutic targets for tauopathies and provides critical quantitative information for pharmacokinetic modeling required for therapeutic and disease mechanism studies."

A new molecular atlas of tau enables precision diagnostics and drug targeting across neurodegenerative diseases


Graphical abstract



Figure 1 Workflow and quantification of pathological insoluble tau and isoforms across tauopathies and control human subjects


Friday, January 09, 2026

New drug NU-9 shows promise against early Alzheimer's in a mouse model

Good news! New drug development is too slow as this case exemplifies again! Hopefully, in the near future machine learning & AI will accelerate drug development!

"... That’s why a new study from Northwestern University offers so much hope, because if researchers there are correct, their new small-molecule NU-9 drug may be able to stop Alzheimer’s disease long before it begins ruining lives. ..."

"... An experimental drug developed at Northwestern University has demonstrated further promise as an early intervention for Alzheimer’s disease.

In a new study, Northwestern scientists identified a previously unknown highly toxic sub-species of amyloid beta oligomers — toxic clusters of peptides — that appear to drive several of the brain’s earliest changes, including neuronal dysfunction, inflammation and activation of immune cells.

The experimental drug, a small-molecule compound called NU-9, decreased this toxic amyloid beta oligomer subtype and dramatically reduced the damage it causes in a mouse model of Alzheimer’s disease. ..."

"... Conceived about 15 years ago, NU-9 emerged as part of Silverman’s multi-year effort to discover a small molecule compound that could prevent toxic protein aggregate buildup in neurodegenerative diseases. By 2021, NU-9 demonstrated efficacy in animal models of amyotrophic lateral sclerosis (ALS), clearing toxic SOD1 and TDP-43 proteins and restoring health to upper motor neurons. In 2024, it received clearance from the U.S. Food and Drug Administration to begin human clinical trials for ALS. ..."

From the abstract:
"INTRODUCTION
Neuronal degeneration and immune cell activation occur early in Alzheimer's disease (AD), but the responsible molecules remain undetermined. While exogenous amyloid beta oligomers (AβOs) induce neuronal death and gliosis, the role of endogenous AβOs is less defined.

METHODS
Brain sections from 1- to 12-month-old 5xFAD mice were immunolabeled for AβOs, activated glia, phosphorylated transactive response DNA-binding protein 43 kDa (pTDP-43), and other AD markers. Neuropathology was analyzed following 60-day oral treatment with NU-9, a small-molecule AβO inhibitor.

RESULTS
By 8 weeks, AβOs accumulated in the subiculum alongside early reactive astrocytes and activated microglia.
Clinical-stage antibody ACU193 detected AβOs in early-stage degenerating neurons, while NU4-labeled denser deposits in late-stage degenerating neurons. ACU193+ AβOs accumulated on reactive astrocyte surfaces, which also contained pTDP-43, and later emerged inside activated microglia.
NU-9 reduced astrocyte-associated ACU193+ AβOs, pTDP-43, and markedly diminished glial fibrillary acidic protein.

DISCUSSION
These findings demonstrate in vivo efficacy of NU-9 and support targeting ACU193+ AβOs to mitigate AD progression.

Highlights
  • ACU193+ AβOs accumulated as puncta in neurons at an early stage of degeneration, while NU4+ AβOs appeared as dense deposits only in late-stage degenerating neurons.
  • The onset and progression of ACU193+ AβOs paralleled activated microglia and reactive astrocytes.
  • ACU193+ AβOs significantly increased on reactive astrocyte surfaces, as NU4+ AβOs accumulated in halos around Thio-S+ plaque cores.
  • In older mice, the ACU193 signal decreased on astrocytes and was found inside activated microglia.
  • Sixty-day oral NU-9 treatment significantly reduced astrocyte ACU193+ AβOs and markedly decreased reactive astrogliosis.
..."

New drug NU-9 shows promise against early Alzheimer's

NU-9 halts Alzheimer’s disease in animal model before symptoms begin (original news release) "Study uncovers a new Alzheimer’s trigger — and a way to stop it"



Fig. 8 Oral treatment with NU-9 reduces astrocyte-associated ACU193+ amyloid beta oligomers and pTDP-43+ ubiquitinated aggregates, and rescues GFAP levels.


Saturday, December 06, 2025

How antibody therapy clears Alzheimer's plaques: Key immune mechanism identified

Good news!

"Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline. ...

They showed that the "Fc fragment" of this monoclonal antibody is essential for engaging microglia—the immune cells of the brain—thus initiating the cellular machinery needed for plaque removal. This is the first direct mechanistic explanation for how this class of therapies works. It clarifies uncertainties in the field and offers a blueprint for developing safer, more effective Alzheimer's treatments.  ...

They identified key cellular machinery needed to clear the amyloid plaques: namely, phagocytosis and lysosomal activity.

Without the Fc fragment, none of these critical cellular processes were triggered. ...  uncovered a microglial gene program, marked by strong expression of the gene SPP1.  ..."

From the abstract:
"Controversies over anti-amyloid immunotherapies underscore the need to elucidate their mechanisms of action.
Here we demonstrate that Lecanemab, a leading anti-β-amyloid (Aβ) antibody, mediates amyloid clearance by activating microglial effector functions.
Using a human microglia xenograft mouse model, we show that Lecanemab significantly reduces Aβ pathology and associated neuritic damage, while neither fragment crystallizable (Fc)-silenced Lecanemab nor microglia deficiency elicits this effect despite intact plaque binding.
Single-cell RNA sequencing and spatial transcriptomic analyses reveal that Lecanemab induces a focused transcriptional program that enhances phagocytosis, lysosomal degradation, metabolic reprogramming, interferon γ genes and antigen presentation.
Finally, we identify SPP1/osteopontin as a major factor induced by Lecanemab treatment and demonstrate its role in promoting Aβ clearance.
These findings highlight that effective amyloid removal depends on the engagement of microglia through the Fc fragment, providing critical insights for optimizing anti-amyloid therapies in Alzheimer’s disease."

How antibody therapy clears Alzheimer's plaques: Key immune mechanism identified

New immune process identified that may alleviate Alzheimer's disease (original news release)



Fig. 1: Lecanemab drives strong transcriptional changes in human microglia associated with Aβ plaques.


Fig. 2: Lecanemab alleviates Aβ pathology by triggering effector functions in the microglia.


Friday, December 05, 2025

How the Brain Protects Itself from Alzheimer’s Disease

Good news!

"Key points
  • High levels of calcium are toxic to cells and contribute to loss of neurons in Alzheimer’s disease.
  • Researchers found that a protein that protects cells from elevated calcium declines with age.
  • Treatments that target the protein might help prevent neurodegeneration.
...

Glyoxalase 1 (GLO1) is a protein that plays an essential role in getting rid of toxic byproducts in cells. In the study, ... researchers discovered elevated GLO1 levels in the brains of animals with excessive levels of cellular calcium, finding that the brain increased GLO1 expression as a protective mechanism to mitigate the effects of the calcium dysregulation.

However, with advancing age, GLO1 activity declined, the researchers found, which may make the brain less resilient to neurodegeneration. The study could inform the development of therapeutics that target GLO1 and prevent neurodegeneration. ..."

From the abstract:
"Alzheimer disease (AD) is characterized by plaques and tangles, including calcium dysregulation and glycated products produced by reactive carbonyl compounds. AD brains have increased glyoxalase I (GLO1), a major scavenger of inflammatory carbonyl compounds, at early, but not later, stages of disease. Calcium dysregulation includes calcium leak from phosphorylated ryanodine receptor 2 (pS2808-RyR2), seen in aged macaques and AD mouse models, but the downstream consequences of calcium leak remain unclear.
Here, we show that chronic calcium leak is associated with increased GLO1 expression and activity.
In macaques, we found age-related increases in GLO1 expression in the prefrontal cortex (PFC), correlating with pS2808-RyR2, and localized to dendrites and astrocytes. To examine the relationship between GLO1 and RyR2, we used S2808D-RyR2 mutant mice exhibiting chronic calcium leak through RyR2, and found increased GLO1 expression and activity in the PFC and hippocampus as early as 1 month and as late as 21 months of age, with a bell-shaped aging curve. These aged S2808D-RyR2 mice demonstrated impaired working memory. As with macaques, GLO1 was expressed in astrocytes and neurons.
Proteomics data generated from S2808D-RyR2 synaptosomes confirmed GLO1 upregulation. Altogether, these data suggest potential association between GLO1 and chronic calcium leak, providing resilience in early stages of aging."

How the Brain Protects Itself from Alzheimer’s Disease | Yale School of Medicine



Fig. 1 GLO1 expression increases with age and correlates with p-S2808-RyR2 in the rhesus macaque brain.


Sunday, November 16, 2025

NAD+ Corrects RNA Splicing to Restore Alzheimer's Memory

Good news!

"Boosting levels of a certain molecule that declines with age was found to restore memory and brain function in Alzheimer’s disease (AD) models – not just by improving energy metabolism, as previously thought, but by fixing RNA splicing errors that disrupt hundreds of genes crucial to neuron health. ...

a team of scientists ... has uncovered a mechanism driven by the natural metabolite, oxidized nicotinamide adenine dinucleotide (NAD⁺), which can shield the brain from the progressive damage of AD. ...

"Preliminary studies have shown that supplementation with NAD⁺ precursors, such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), can offer therapeutic benefits in AD animal models and early clinical trials," ... "However, the molecular mechanisms behind these benefits remain largely unclear." ..."

"... The new study reveals that NAD⁺ works through a previously unidentified RNA-splicing pathway. This pathway is regulated by a protein called EVA1C, which plays an essential role in the process of RNA splicing. RNA splicing allows a single gene to produce multiple isoforms of a protein, and one isoform may show distinctive effects to the other isoforms. Its dysregulation is one of the most recently acknowledged risk factor for AD.

The researchers discovered that when NAD⁺ levels are increased, EVA1C helps correct mistakes in RNA splicing. This restoration process improves the function of hundreds of genes, many crucial for brain health, which can help reverse the neurodegenerative damage caused by tau. ..."

From the abstract:
"Dysfunctional alternative splicing events (ASEs) in RNA are markers of aging and Alzheimer’s disease (AD).
As a key neuronal resilience metabolite, the oxidized nicotinamide adenine dinucleotide (NAD+) slows down AD progression in preclinical studies with several clinical trials ongoing. However, the underlying molecular mechanisms around how NAD+ enhances neuronal resilience, especially whether it has any effect on ASEs, have remained elusive.
This study shows that NAD+ augmentation corrects the ASEs of many genes via a key protein, EVA1C (epithelial V-like antigen 1 homolog C), which is involved in neuronal development and activities.
EVA1C is reduced in the hippocampus in patients with AD compared to cognitively normal ones.
NAD+-induced memory retention is partially dependent on EVA1C, as adeno-associated virus–based Eva1c knockdown in the hippocampal CA1 region annuls NAD+-induced memory improvement in pathological Tau–bearing mice.
We propose that NAD+ reduces AD pathologies, at least partially, via amplification of the NAD+-EVA1C splicing axis, pointing to a potential splice-switching therapy for AD."

NAD+ Corrects RNA Splicing to Restore Alzheimer's Memory

NAD⁺ restores memory in Alzheimer’s’ disease models by correcting RNA errors "A groundbreaking international study shows how boosting a natural molecule can help restore memory in animal models of Alzheimer’s disease. The new study offers hope for developing new therapies for patients with Alzheimer’s disease."



Fig. 1. Compromised mRNA splicing in Tau pathology and aging.


Monday, October 13, 2025

Scientists reverse Alzheimer's in mice using nanoparticles

Good news!

"... Unlike traditional nanomedicine, which relies on nanoparticles as carriers for therapeutic molecules, this approach employs nanoparticles that are bioactive in their own right: "supramolecular drugs." ...

Instead of targeting neurons directly, the therapy restores the proper function of the blood-brain barrier (BBB) ... By repairing this critical interface, the researchers achieved a reversal of Alzheimer's pathology in animal models. ...

The team demonstrated that targeting a specific mechanism enables undesirable "waste proteins" produced in the brain to pass through this barrier and be eliminated in the blood flow. In Alzheimer's disease, the main "waste" protein is amyloid-β (Aβ), whose accumulation impairs the normal functioning of the neurons. ..."

From the abstract:
"The blood‒brain barrier (BBB) is a highly selective permeability barrier that safeguards the central nervous system (CNS) from potentially harmful substances while regulating the transport of essential molecules. Its dysfunction is increasingly recognized as a pivotal factor in the pathogenesis of Alzheimer’s disease (AD), contributing to the accumulation of amyloid-β (Aβ) plaques.
We present a novel therapeutic strategy that targets low-density lipoprotein receptor-related protein 1 (LRP1) on the BBB. Our design leverages the multivalent nature and precise size of LRP1-targeted polymersomes to modulate receptor-mediated transport, biasing LRP1 trafficking toward transcytosis and thereby upregulating its expression to promote efficient Aβ removal.
In AD model mice, this intervention significantly reduced brain Aβ levels by nearly 45% and increased plasma Aβ levels by 8-fold within 2 h, as measured by ELISA.
Multiple imaging techniques confirmed the reduction in brain Aβ signals after treatment.
Cognitive assessments revealed that treated AD mice exhibited significant improvements in spatial learning and memory, with performance levels comparable to those of wild-type mice.
These cognitive benefits persisted for up to 6 months post-treatment.
This work pioneers a new paradigm in drug design, where function arises from the supramolecular nature of the nanomedicine, harnessing multivalency to elicit biological action at the membrane trafficking level.
Our findings also reaffirm the critical role of the BBB in AD pathogenesis and demonstrate that targeting the BBB can make therapeutic interventions significantly more effective.
We establish a compelling case for BBB modulation and LRP1-mediated Aβ clearance as a transformative foundation for future AD therapies."

Scientists reverse Alzheimer's in mice using nanoparticles



Fig. 1 Schematics of LRP1 shuttling across brain endothelial cells




Monday, October 06, 2025

Alzheimer’s precursor protein may boost aging immune system and improves antitumor immunity

Amazing stuff!

"A protein notorious for its role in Alzheimer’s disease may hold the key to supercharging the aging immune system, according to new research. Scientists have found that a byproduct of amyloid-beta rejuvenates T cells, boosting their tumor-fighting power and dramatically reducing cancer risk. ...

In the present study, five years of nationally representative surveys were analyzed, and the researchers found that adults over 59 with Alzheimer’s disease were a staggering 21 times less likely to develop cancer than those without the disease. ..."

"... Their new study ... reveals how a protein tied to Alzheimer’s disease also strengthens the immune system, offering insights that could inspire innovative treatments for cancer, aging and neurodegenerative diseases. ...

To test this finding, the researchers transplanted mitochondria from Alzheimer’s T-cells into aging T-cells that did not have Alzheimer’s. ...

“Older T-cells began functioning like young, active T-cells again. That was an incredible finding because it suggests a whole new way to think about rejuvenating the immune system.”

The results also revealed that amyloid beta contributes to cancer in another way – by depleting fumarate, a small molecule made inside mitochondria during energy production. Fumarate acts like a brake, keeping mitophagy from running out of control. When fumarate levels drop, cells recycle too many of their healthy mitochondria, resulting in a loss of strength. ..."

From the abstract:
"Patients with Alzheimer's disease (AD) have a decreased incidence of cancer, with a cross-sectional analysis of a nationwide sample of adults finding 21-fold higher odds of cancer diagnosis in non-AD individuals compared with those with AD.
In this study, we demonstrated that mitochondrial localization of AD-associated amyloid-β precursor protein (APP) and its cleavage product amyloid-β 40, but not mutant APP that lacks a mitochondrial localization signal, inhibits lipid stress–mediated hyperactive mitophagy in aging T cells, improving their antitumor functions.
Growth of melanoma xenograft or carcinogen-induced oral cancer models was highly reduced in AD mice. Additionally, adoptive cell transfer–based immunotherapy using aging T cells isolated from AD mice suppressed tumor growth.
The metabolic signature of stress-dependent mitophagy in T cells showed fumarate depletion, which was linked to decreased succination of Parkin and enhanced mitochondrial damage.
Mechanistically, APP interaction with the TOMM complex at the outer mitochondrial membrane attenuated trafficking of ceramide synthase CerS6 to mitochondria in aging AD T cells, preventing ceramide-dependent mitophagy. Thus, APP restored mitochondrial fumarate metabolism and Parkin succination, improving antitumor functions of AD T cells in vitro and in vivo.
Exogenous fumarate supplementation or healthy AD mitochondria transfer functionally mimicked the AD/APP phenotype in aging T cells, enhancing their antitumor activity to control tumor growth.
Moreover, T cells isolated from aging donors showed elevated mitophagy with fumarate depletion, which was restored in T cells isolated from age-matched patients with AD.
Together, these findings show that AD protects T cells against ceramide-dependent mitophagy and fumarate depletion to enhance antitumor functions."

Alzheimer’s protein may boost aging immune system


Sunday, October 05, 2025

Neurons may use newly discovered nanotubes to communicate and spread disease

Amazing stuff! This could be huge!

"Neuroscientists have been studying synapses, the fundamental junctions that allow rapid communication between neurons, for well over a century. But now, a research team has identified a different set of neuronal connections in the brain—one that might bypass synapses altogether.

Using high-resolution images of mouse and human brains, the researchers documented a network of tubes, each about 3 micrometers long and just a few hundred nanometers thick, connecting neurons to one another.
In mouse cells, the team found evidence of neuron-to-neuron transfer of electrical signals via these nanotubes. They also showed that beta amyloid, a protein implicated in Alzheimer’s disease, moved along these tubes from one cell to the next when inserted into mouse neurons. ..."

From the editor's summary and abstract:
"Editor’s summary
Synaptic connections mediate classical intercellular communication in the brain. However, recent data have demonstrated the existence of noncanonical routes of interneuronal communication mediating the transport of materials including calcium, mitochondria, and pathogenic proteins such as amyloid beta (Aβ). Using super-resolution and electron microscopy, Chang et al. identified and characterized structures called nanotubular bridges that connect dendrites in the brain ... These bridges mediate the transport of calcium ions, small molecules, and Aβ peptides, and may contribute to the spreading and accumulation of pathological Aβ in Alzheimer’s disease. ...

Structured Abstract
INTRODUCTION
Communication between neurons is fundamental to brain function and has long been thought to occur primarily through specialized junctions called synapses. However, the observed transfer of large molecules and proteins between neurons suggests the existence of other, less understood communication pathways.
In other biological systems, long-range intercellular transport is mediated by ultrathin membrane bridges known as nanotubes.
These structures can transport a vast range of materials, from small ions (10−10 m) to large mitochondria (10−6 m). Despite their potential importance, the fragile, dynamic nature of nanotubes and a lack of specific markers have made them difficult to study in tissue, leaving their existence and physiological role in the brain unconfirmed. We hypothesized that a network of these nanotubes forms an additional layer of neuronal connectivity, operating in parallel with synapses.

RATIONALE
In other cell types, nanotubes often form when thin, exploratory cell protrusions contact a neighboring cell and establish a stable connection.
In the brain, dendritic protrusions, known as filopodia, have historically been viewed only as precursors to synapses.
The possibility that they could form nonsynaptic connections with other dendrites has been largely overlooked.
Our investigation began by reexamining existing high-resolution electron microscopy images of mouse and human brain tissue. We discovered instances where a filopodium from one neuron’s dendrite formed a direct, membrane-to-membrane contact with the dendrite of a neighboring neuron without any of the typical structural features of a chemical synapse. This observation led us to propose that these were a previously unidentified form of neuronal connection: dendritic nanotubes.

RESULTS
By using advanced superresolution microscopy on specially prepared mouse brain tissue, we visualized these dendritic nanotubes connecting pyramidal neurons in the primary visual cortex.
A machine learning–based classification confirmed that their shape was distinct from that of synaptic structures.
In cultured neurons, we observed these nanotubes forming dynamically and confirmed that they possessed a distinct internal structure, setting them apart from other neuronal extensions.
Functionally, these neuronal nanotubes created a path for calcium signals to travel between connected neurons; blocking nanotube formation halted this nonsynaptic transfer.

To test whether these nanotubular structures could transport disease-related molecules, we injected human β-amyloid (Aβ), a peptide central to Alzheimer’s disease (AD), into a single neuron in a mouse brain slice. The peptides spread to neighboring neurons, and this propagation was stopped when nanotube formation was inhibited, confirming that the nanotubes acted as direct conduits.

Lastly, we investigated the role of these dendritic nanotubes in a mouse model of AD. We found that the nanotube network was significantly altered early in the disease, even before the formation of amyloid plaques, a hallmark of AD.
Our computational model supported these findings, predicting that overactivation in the nanotube network could accelerate the toxic accumulation of amyloid in specific neurons, thereby providing a mechanistic link between nanotube alterations and the progression of AD pathology.

CONCLUSION
This study provides the first comprehensive characterization of a nanotubular communication network in the brain, establishing a new framework for nonsynaptic signaling between neurons. By demonstrating that these dendritic nanotubes can transport disease-implicated proteins, such as Aβ, we have revealed a previously unknown mechanism that may contribute to the spread of pathology in the early stages of neurodegenerative disorders. The discovery of this parallel neural network opens up entirely new avenues for research into brain connectivity, intercellular communication, and the fundamental processes driving neurological disease."

ScienceAdviser

Hidden networks in the brain (Perspective, no public access)




Neuronal nanotubes mediate intercellular transport and disease.


Supplementary Figure 1.
Nonsynaptic dendritic filopodia contacting other dendrites in the EM-resolved mouse brain


Figure 1. Dendritic nanotubes (DNTs) in dissociated cortical neurons